Telix Pharmaceuticals Limited
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $803.8M | $516.6M | $333.0M |
| Cost of Revenue | $377.4M | $180.4M | $123.4M |
| Gross Profit | $426.4M | $336.2M | $209.5M |
| Gross Margin | 53.1% | 65.1% | 62.9% |
| Operating Expenses | |||
| Research & Development | — | — | — |
| SG&A Expense | — | — | — |
| Operating Income | $29.8M | $55.2M | $11.0M |
| Operating Margin | 3.7% | 10.7% | 3.3% |
| Interest Expense | $181.0K | $64.0K | $97.0K |
| Pretax Income | $-5.3M | $37.9M | $2.6M |
| Income Tax Expense | $1.9M | $4.2M | $-1.6M |
| Net Income | $-7.1M | $33.7M | $4.2M |
| Net Margin | -0.9% | 6.5% | 1.3% |
| EPS (Basic) | $-0.02 | $0.10 | $0.01 |
| EPS (Diluted) | $-0.02 | $0.10 | $0.01 |
| Shares Outstanding (Basic) | 338.8M | 334.7M | — |
| Shares Outstanding (Diluted) | 338.8M | 334.7M | — |
| Dividends Per Share | — | — | — |